Integra Total Current Assets vs Accounts Payable Analysis

IART Stock

USD 30.90 0.10 0.32%

Integra LifeSciences financial indicator trend analysis is infinitely more than just investigating Integra LifeSciences recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Integra LifeSciences is a good investment. Please check the relationship between Integra LifeSciences Total Current Assets and its Accounts Payable accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Integra LifeSciences Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

Total Current Assets vs Accounts Payable

Total Current Assets vs Accounts Payable Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Integra LifeSciences Total Current Assets account and Accounts Payable. At this time, the significance of the direction appears to have strong relationship.

The correlation between Integra LifeSciences' Total Current Assets and Accounts Payable is 0.78. Overlapping area represents the amount of variation of Total Current Assets that can explain the historical movement of Accounts Payable in the same time period over historical financial statements of Integra LifeSciences Holdings, assuming nothing else is changed. The correlation between historical values of Integra LifeSciences' Total Current Assets and Accounts Payable is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Current Assets of Integra LifeSciences Holdings are associated (or correlated) with its Accounts Payable. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Accounts Payable has no effect on the direction of Total Current Assets i.e., Integra LifeSciences' Total Current Assets and Accounts Payable go up and down completely randomly.

Correlation Coefficient

0.78

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Total Current Assets

The total value of all assets that are expected to be converted into cash within one year or during the normal operating cycle.

Accounts Payable

An accounting item on the balance sheet that represents Integra LifeSciences obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Integra LifeSciences are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Most indicators from Integra LifeSciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Integra LifeSciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Integra LifeSciences Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

At this time, Integra LifeSciences' Sales General And Administrative To Revenue is comparatively stable compared to the past year. Enterprise Value is likely to gain to about 442.9 M in 2024, whereas Selling General Administrative is likely to drop slightly above 339.5 M in 2024.

	2021	2022	2023	2024 (projected)
Gross Profit	944.6M	970.3M	888.4M	458.0M
Total Revenue	1.5B	1.6B	1.5B	1.6B

Gross Profit Total Revenue

Integra LifeSciences fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Intangible Assets	Short Long Term Debt Total	Common Stock Total Equity	Short Term Investments	Short Term Debt
Total Assets		0.97	0.87	0.97	0.95	0.94	0.83	0.86	0.81	0.99	-0.27	0.83	0.96	0.81	0.99	0.93	0.68	0.78	0.99	0.85	0.96	0.97	0.98	0.85	0.68	0.01
Other Current Liab	0.97		0.89	0.92	0.87	0.94	0.75	0.81	0.8	0.97	-0.12	0.81	0.94	0.82	0.97	0.9	0.69	0.78	0.98	0.77	0.94	0.96	0.98	0.84	0.61	0.0
Total Current Liabilities	0.87	0.89		0.81	0.73	0.84	0.55	0.75	0.78	0.85	-0.23	0.77	0.84	0.83	0.86	0.74	0.84	0.87	0.88	0.56	0.86	0.87	0.89	0.9	0.37	0.0
Total Stockholder Equity	0.97	0.92	0.81		0.96	0.84	0.87	0.82	0.85	0.96	-0.34	0.86	0.92	0.8	0.92	0.92	0.65	0.79	0.92	0.88	0.96	0.92	0.91	0.84	0.7	0.03
Property Plant And Equipment Net	0.95	0.87	0.73	0.96		0.84	0.91	0.87	0.76	0.94	-0.27	0.79	0.91	0.73	0.91	0.95	0.53	0.66	0.9	0.93	0.92	0.87	0.88	0.76	0.76	-0.01
Net Debt	0.94	0.94	0.84	0.84	0.84		0.69	0.88	0.62	0.95	-0.11	0.64	0.95	0.76	0.98	0.88	0.62	0.7	0.98	0.71	0.84	0.96	0.98	0.8	0.57	-0.04
Retained Earnings	0.83	0.75	0.55	0.87	0.91	0.69		0.71	0.77	0.8	-0.36	0.81	0.74	0.51	0.78	0.86	0.45	0.39	0.78	0.97	0.86	0.71	0.76	0.58	0.88	-0.11
Accounts Payable	0.86	0.81	0.75	0.82	0.87	0.88	0.71		0.55	0.87	-0.31	0.57	0.93	0.68	0.86	0.85	0.43	0.63	0.86	0.74	0.78	0.85	0.86	0.72	0.48	-0.16
Cash	0.81	0.8	0.78	0.85	0.76	0.62	0.77	0.55		0.76	-0.41	1.0	0.67	0.6	0.75	0.68	0.76	0.65	0.76	0.75	0.91	0.72	0.77	0.68	0.64	0.01
Non Current Assets Total	0.99	0.97	0.85	0.96	0.94	0.95	0.8	0.87	0.76		-0.25	0.78	0.97	0.81	0.99	0.93	0.64	0.79	0.99	0.84	0.93	0.99	0.98	0.86	0.66	0.02
Non Currrent Assets Other	-0.27	-0.12	-0.23	-0.34	-0.27	-0.11	-0.36	-0.31	-0.41	-0.25		-0.4	-0.22	-0.18	-0.21	-0.14	-0.21	-0.21	-0.2	-0.35	-0.3	-0.23	-0.2	-0.24	-0.15	0.04
Cash And Short Term Investments	0.83	0.81	0.77	0.86	0.79	0.64	0.81	0.57	1.0	0.78	-0.4		0.68	0.59	0.77	0.71	0.75	0.63	0.78	0.79	0.92	0.73	0.78	0.69	0.69	0.0
Net Receivables	0.96	0.94	0.84	0.92	0.91	0.95	0.74	0.93	0.67	0.97	-0.22	0.68		0.85	0.95	0.93	0.6	0.79	0.96	0.76	0.89	0.96	0.95	0.85	0.53	0.0
Common Stock Shares Outstanding	0.81	0.82	0.83	0.8	0.73	0.76	0.51	0.68	0.6	0.81	-0.18	0.59	0.85		0.79	0.8	0.62	0.88	0.79	0.52	0.78	0.83	0.78	0.87	0.25	0.27
Non Current Liabilities Total	0.99	0.97	0.86	0.92	0.91	0.98	0.78	0.86	0.75	0.99	-0.21	0.77	0.95	0.79		0.92	0.66	0.74	1.0	0.81	0.92	0.98	1.0	0.83	0.66	0.0
Inventory	0.93	0.9	0.74	0.92	0.95	0.88	0.86	0.85	0.68	0.93	-0.14	0.71	0.93	0.8	0.92		0.54	0.64	0.92	0.85	0.91	0.88	0.9	0.75	0.67	0.0
Other Current Assets	0.68	0.69	0.84	0.65	0.53	0.62	0.45	0.43	0.76	0.64	-0.21	0.75	0.6	0.62	0.66	0.54		0.68	0.69	0.38	0.77	0.64	0.7	0.68	0.4	0.01
Other Stockholder Equity	0.78	0.78	0.87	0.79	0.66	0.7	0.39	0.63	0.65	0.79	-0.21	0.63	0.79	0.88	0.74	0.64	0.68		0.75	0.44	0.73	0.82	0.74	0.87	0.21	0.2
Total Liab	0.99	0.98	0.88	0.92	0.9	0.98	0.78	0.86	0.76	0.99	-0.2	0.78	0.96	0.79	1.0	0.92	0.69	0.75		0.8	0.93	0.98	1.0	0.84	0.65	0.0
Property Plant And Equipment Gross	0.85	0.77	0.56	0.88	0.93	0.71	0.97	0.74	0.75	0.84	-0.35	0.79	0.76	0.52	0.81	0.85	0.38	0.44	0.8		0.84	0.76	0.78	0.62	0.88	-0.08
Total Current Assets	0.96	0.94	0.86	0.96	0.92	0.84	0.86	0.78	0.91	0.93	-0.3	0.92	0.89	0.78	0.92	0.91	0.77	0.73	0.93	0.84		0.88	0.93	0.8	0.69	-0.01
Intangible Assets	0.97	0.96	0.87	0.92	0.87	0.96	0.71	0.85	0.72	0.99	-0.23	0.73	0.96	0.83	0.98	0.88	0.64	0.82	0.98	0.76	0.88		0.97	0.87	0.58	0.04
Short Long Term Debt Total	0.98	0.98	0.89	0.91	0.88	0.98	0.76	0.86	0.77	0.98	-0.2	0.78	0.95	0.78	1.0	0.9	0.7	0.74	1.0	0.78	0.93	0.97		0.83	0.63	-0.03
Common Stock Total Equity	0.85	0.84	0.9	0.84	0.76	0.8	0.58	0.72	0.68	0.86	-0.24	0.69	0.85	0.87	0.83	0.75	0.68	0.87	0.84	0.62	0.8	0.87	0.83		0.42	0.28
Short Term Investments	0.68	0.61	0.37	0.7	0.76	0.57	0.88	0.48	0.64	0.66	-0.15	0.69	0.53	0.25	0.66	0.67	0.4	0.21	0.65	0.88	0.69	0.58	0.63	0.42		-0.12
Short Term Debt	0.01	0.0	0.0	0.03	-0.01	-0.04	-0.11	-0.16	0.01	0.02	0.04	0.0	0.0	0.27	0.0	0.0	0.01	0.2	0.0	-0.08	-0.01	0.04	-0.03	0.28	-0.12

Click cells to compare fundamentals

Integra LifeSciences Account Relationship Matchups

Integra LifeSciences fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	3.3B	3.6B	3.8B	3.9B	3.8B	4.0B
Other Current Liab	156.2M	182.1M	213.1M	158.8M	176.3M	185.1M
Total Current Liabilities	331.3M	401.0M	340.0M	320.9M	307.0M	158.9M
Total Stockholder Equity	1.4B	1.5B	1.7B	1.8B	1.6B	1.7B
Property Plant And Equipment Net	431.9M	371.2M	396.2M	459.6M	496.4M	521.2M
Net Debt	1.3B	1.2B	1.1B	1.2B	1.4B	1.5B
Retained Earnings	398.6M	532.3M	698.6M	879.1M	946.9M	994.2M
Accounts Payable	113.1M	54.6M	61.8M	102.1M	92.3M	96.9M
Cash	198.9M	470.2M	513.4M	456.7M	276.4M	290.2M
Non Current Assets Total	2.4B	2.4B	2.6B	2.7B	2.7B	2.9B
Non Currrent Assets Other	11.2M	11.3M	10.0M	(510.2M)	26.0M	27.3M
Cash And Short Term Investments	198.9M	470.2M	513.4M	456.7M	309.1M	324.6M
Net Receivables	275.3M	225.5M	231.8M	263.5M	259.3M	272.3M
Common Stock Shares Outstanding	86.5M	85.2M	85.5M	83.5M	80.3M	67.2M
Liabilities And Stockholders Equity	3.3B	3.6B	3.8B	3.9B	3.8B	4.0B
Non Current Liabilities Total	1.6B	1.7B	1.8B	1.8B	1.9B	2.0B
Inventory	316.1M	310.1M	317.4M	324.6M	389.6M	409.1M
Other Current Assets	67.9M	231.4M	91.1M	116.8M	100.0M	51.5M
Other Stockholder Equity	1.1B	1.1B	1.0B	914.1M	655.2M	467.2M
Total Liab	1.9B	2.1B	2.1B	2.1B	2.2B	2.3B
Property Plant And Equipment Gross	431.9M	371.2M	711.1M	789.3M	863.8M	907.0M
Total Current Assets	858.2M	1.2B	1.2B	1.2B	1.1B	1.1B
Accumulated Other Comprehensive Income	(76.4M)	(74.1M)	(45.2M)	10.3M	(15.1M)	(15.9M)
Intangible Assets	1.0B	989.4M	1.1B	1.1B	1.1B	1.1B
Short Long Term Debt Total	1.5B	1.7B	1.7B	1.6B	1.7B	1.8B
Common Stock Total Equity	887K	893K	896K	905K	1.0M	528.7K
Short Term Investments	1.5M	4.7M	12K	16.7M	32.7M	34.3M
Short Term Debt	57.3M	159.1M	59.8M	52.7M	29.8M	28.3M
Common Stock	887K	893K	896K	905K	909K	547.5K
Other Liab	116.1M	131.2M	135.9M	201.8M	232.1M	243.7M
Other Assets	27.3M	168.6M	3.8B	63.2M	72.6M	69.0M
Long Term Debt	1.2B	1.4B	1.4B	1.3B	1.5B	749.7M
Treasury Stock	(119.9M)	(235.1M)	(234.4M)	(362.9M)	(326.6M)	(310.2M)
Property Plant Equipment	337.4M	287.5M	311.7M	311.3M	358.0M	375.9M
Current Deferred Revenue	4.8M	5.3M	5.3M	7.3M	8.5M	5.3M
Good Will	954.3M	932.4M	1.0B	1.0B	1.1B	1.1B
Net Tangible Assets	(569.1M)	(406.9M)	(474.2M)	(361.1M)	(325.0M)	(341.2M)
Retained Earnings Total Equity	398.6M	532.3M	698.6M	879.1M	1.0B	1.1B
Long Term Debt Total	1.2B	1.4B	1.4B	1.3B	1.5B	1.0B
Capital Surpluse	1.2B	1.3B	1.3B	1.3B	1.5B	1.0B

Pair Trading with Integra LifeSciences

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Integra LifeSciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Integra LifeSciences will appreciate offsetting losses from the drop in the long position's value.

Moving together with Integra Stock

0.82	AHG	Akso Health Group	Pair Corr
0.89	CAH	Cardinal Health Fiscal Year End 20th of August 2024	Pair Corr

Moving against Integra Stock

0.82	WGS	GeneDx Holdings Corp	Pair Corr
0.69	GCTK	GlucoTrack	Pair Corr
0.6	ESTA	Establishment Labs	Pair Corr
0.54	INGN	Inogen Inc	Pair Corr

The ability to find closely correlated positions to Integra LifeSciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Integra LifeSciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Integra LifeSciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Integra LifeSciences Holdings to buy it.

The correlation of Integra LifeSciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Integra LifeSciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Integra LifeSciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Integra LifeSciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Integra LifeSciences is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Integra Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Integra Lifesciences Holdings Stock. Highlighted below are key reports to facilitate an investment decision about Integra Lifesciences Holdings Stock:

How To Invest In Integra

Details

Is Integra Stock a good investment?

Details

What is Integra LifeSciences' Net Worth?

Details

Largest Health Care Equipment & Supplies Companies

View

Largest Health Care Equipment & Services Companies

View

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Integra LifeSciences Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.

Complementary Tools for Integra Stock analysis

When running Integra LifeSciences' price analysis, check to measure Integra LifeSciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Integra LifeSciences is operating at the current time. Most of Integra LifeSciences' value examination focuses on studying past and present price action to predict the probability of Integra LifeSciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Integra LifeSciences' price. Additionally, you may evaluate how the addition of Integra LifeSciences to your portfolios can decrease your overall portfolio volatility.

	Money Managers Screen money managers from public funds and ETFs managed around the world
	Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
	Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum
	Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
	Fundamental Analysis View fundamental data based on most recent published financial statements
	FinTech Suite Use AI to screen and filter profitable investment opportunities
	Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments

Is Integra LifeSciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Integra LifeSciences. If investors know Integra will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Integra LifeSciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.60)

Earnings Share

0.51

Revenue Per Share

19.349

Quarterly Revenue Growth

(0.03)

Return On Assets

0.0383

The market value of Integra LifeSciences is measured differently than its book value, which is the value of Integra that is recorded on the company's balance sheet. Investors also form their own opinion of Integra LifeSciences' value that differs from its market value or its book value, called intrinsic value, which is Integra LifeSciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Integra LifeSciences' market value can be influenced by many factors that don't directly affect Integra LifeSciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Integra LifeSciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Integra LifeSciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Integra LifeSciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Integra Total Current Assets vs Accounts Payable Analysis

Total Current Assets vs Accounts Payable

Total Current Assets vs Accounts Payable Correlation Analysis

Correlation Coefficient

Total Current Assets

Accounts Payable

Integra LifeSciences fundamental ratios Correlations

Integra LifeSciences Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Integra LifeSciences fundamental ratios Accounts

Pair Trading with Integra LifeSciences

Moving together with Integra Stock

Moving against Integra Stock

Complementary Tools for Integra Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Cash
Total Liab	+ 1.0	Non Current Liabilities Total
Short Long Term Debt Total	+ 1.0	Non Current Liabilities Total
Short Long Term Debt Total	+ 1.0	Total Liab
Non Current Assets Total	+ 0.99	Total Assets
Non Current Liabilities Total	+ 0.99	Total Assets

Non Currrent Assets Other	- 0.41	Cash
Cash And Short Term Investments	- 0.4	Non Currrent Assets Other
Non Currrent Assets Other	- 0.36	Retained Earnings
Property Plant And Equipment Gross	- 0.35	Non Currrent Assets Other
Non Currrent Assets Other	- 0.34	Total Stockholder Equity
Non Currrent Assets Other	- 0.31	Accounts Payable